Shreya Biswas

Featured in: Favicon

medium.com Favicon

wiley.com

timeslive.co.za Favicon

mining.com Favicon

sowetanlive.co.za Favicon

businesslive.co.za Favicon

inuth.com

westlaw.com Favicon

emeraldgrouppublishing.com Favicon

smenet.org + 5 more

Articles

Delta, Korean Air to buy 25% Stake in Canada's WestJet

6 days ago | gurutrade.com | Sameer Manekar |Shreya Biswas

May 9 (Reuters) - Delta Air Lines and Korean Air Lines will acquire an aggregate 25% stake in Canada's WestJet Airlines for $550 million from private equity firm Onex Corp, the U.S. carrier said on Friday. The deal, where Delta will invest $330 million for a 15% stake in WestJet and Korean Air will invest $220 million for a 10% interest, deepens the airlines' presence in the North American market.
AMETEK to acquire FARO Technologies in deal valued at $920 million

1 week ago | today.westlaw.com | Sameer Manekar |Aatreyee Dasgupta |Tasim Zahid |Shreya Biswas

(Reuters) -Industrial tools maker AMETEK will acquire FARO Technologies at an enterprise value of about $920 million, the two companies said on Tuesday, sending the target firm's shares soaring 36% before the bell. Under the agreement, AMETEK is...
EnQuest bows out of Serica deal as market jitters hinder agreement on terms

1 week ago | today.westlaw.com | Shinjini Ganguli |Aatrayee Chatterjee |Shreya Biswas |Pushkala Aripaka

(Reuters) -North Sea-focused oil producer EnQuest will not make an offer for UK's Serica Energy, the companies said on Friday, as the two could not agree on favourable terms in time amid market volatility. EnQuest shares were down about 5% at 13.14...
GlobalData gets takeover proposals from funds managed by ICG, KKR

2 weeks ago | today.westlaw.com | Pushkala Aripaka |Shreya Biswas

(Reuters) -Britain's GlobalData said on Wednesday it had received preliminary takeover proposals from funds managed by private equity groups ICG and KKR, sending its shares up as much as 35.9%. The data analytics and consulting company said it was in...
Insurance broker Aon misses quarterly profit estimates on higher cost

2 weeks ago | today.westlaw.com | Shreya Biswas |Prakhar Srivastava

(Reuters) - Insurance brokerage firm Aon missed Wall Street estimates for first-quarter profit on Friday, hurt by higher expenses. Aon increased its total debt to finance the acquisition of NFP. The additional debt led to a rise in its expenses in the...
Regeneron to invest over $3 billion to boost US manufacturing

3 weeks ago | today.westlaw.com | Shinjini Ganguli |Mariam Sunny |Shreya Biswas

(Reuters) -Regeneron Pharmaceuticals said on Tuesday it has signed a deal worth more than $3 billion with contract drug developer Fujifilm Diosynth, potentially doubling its U.S. manufacturing capacity and bringing its total investments in the...
Billionaire Carl Icahn builds 34% economic interest in Bausch Health

3 weeks ago | today.westlaw.com | Shinjini Ganguli |Niket Nishant |Bhanvi Satija |Shreya Biswas

(Reuters) -Billionaire Carl Icahn has built an economic interest covering about 34% of Bausch Health's shares, according to a filing on Tuesday, days after the pharmaceutical firm adopted a "poison pill" to ward off hostile takeovers.
State Street's Quarterly Profit Jumps 39% on Strong Fee Income, Lower Expenses

3 weeks ago | gurutrade.com | Arasu Kannagi Basil |Shreya Biswas

April 17 (Reuters) - Custodian bank State Street on Thursday reported a 39% jump in first-quarter profit, benefitting from lower expenses and higher fees earned from managing client assets. The bank's assets under custody and administration rose 6% to $46.7 trillion in the three months ended March 31 from a year earlier, driven by higher market levels and flows. Its total fee revenue climbed 6% to $2.57 billion in the quarter.
EU authorizes Eisai-Biogen's drug for early Alzheimer's treatment

1 month ago | today.westlaw.com | Sriparna Roy |Alan Barona |Manas Mishra |Shreya Biswas

(Reuters) -The European Commission on Tuesday authorized the use of Eisai and Biogen's drug to treat some patients with mild cognitive impairment in the early stages of Alzheimer's disease, ending a more than two-year-long review process.
US FDA declines to approve Milestone's heart rhythm nasal spray; shares halve

1 month ago | today.westlaw.com | Puyaan Singh |Siddhi Mahatole |Shreya Biswas |Shailesh Kuber

(Reuters) -Milestone Pharmaceuticals said on Friday the U.S. health regulator had declined to approve its nasal spray to treat a type of heart condition and had called for an inspection of the facility that performs the testing of the drug.